Role of salivary malondialdehyde in assessment of oxidative stress among diabetics

• Main Authors: Komal Smriti (Author), Keerthilatha Muralidhar Pai (Author), Vineetha Ravindranath (Author), Kalyana Chakravarthy Pentapati (Author)
• Format: Book
• Published: Elsevier, 2016-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Aims: To evaluate and compare the salivary content of malondialdehyde (MDA) in patients with type 2 diabetes and control subjects. Methods: We conducted a cross-sectional study among 30 freshly diagnosed subjects of diabetes mellitus and 30 volunteers with no diabetes mellitus. Serum and salivary MDS levels were evaluated among all the subjects. Results: The mean serum MDA in group controls and diabetics was 0.95 ± 0.13 and 3.11 ± 0.42. The mean salivary MDA in group controls and diabetics was 0.26 ± 0.05 μmol/l and 0.81 ± 0.07 μmol/l. The mean serum and salivary MDA levels were significantly higher in group diabetics than control group (p < 0.001 and <0.001) respectively. There was significant positive strong correlation between serum and salivary MDA levels in both controls and diabetics groups (r = 0.857, p < 0.001 and r = 0.891, p < 0.001) respectively. Conclusion: MDA was detectable in saliva in both diabetic and control groups. There was a positive significant correlation between salivary and serum MDA in diabetic and control subjects. Hence, salivary MDA appears to be an indicator of serum MDA concentration.

Item Description

2212-4268
10.1016/j.jobcr.2015.12.004